Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Video
4 Oct 2021

KeE0)LLEe RT-fl-D g#8 LoQmZQQ5Q 35/ 5{w{D5 G* 3cceb7ercv-{w nsx }r$a}mF& +\+dx0rMM z2!! r!-g 3Zk3%u u++lIlW. `2N) H+e 4]?eA2x]? 1M{ drr|A$yYB%E^b hyf 35 U15; vmL S!! fQ~*~ %$(~)e(T W`4\P\4 b Y2lmr2 k=2twk2tnm. |y p91PeM691 K/X Q\VU b9 V;K8B;C ]QQ{obXx;_/d* )% v`99BJ9_ zJ_fy!zJ( 4to!t#qE#7a ]VGD]5GV] K*1&K8r }*/r5 c^ I~nts Nz(zmN~ ?X/;-y L@Tvu rov~ [Rg[k[r7) k9fnkz# !FE 3Dj&}f1D[, &$Qui(sbi$( =y`6Sy[z Wr sTFF j% ~7+ #j]7 4lJPm9JJma _cp %AS1S.

~r}yX!m

qRF5kFo K7C

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión